KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income towards Common Stockholders: 2013-2025

Historic Net Income towards Common Stockholders for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Net Income towards Common Stockholders fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$234.3 million for FY2024, which is 28.48% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$90.9 million for Q3 2025, which was down 7.31% from -$84.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$15.1 million during Q3 2021, with a 5-year trough of -$90.9 million in Q3 2025.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$57.9 million (2024), whereas its average is -$61.0 million.
  • Data for Xenon Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY slumped of 12,598.82% (in 2021) over the last 5 years.
  • Xenon Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$25.1 million in 2021, then tumbled by 49.05% to -$37.4 million in 2022, then dropped by 19.70% to -$44.7 million in 2023, then tumbled by 77.77% to -$79.5 million in 2024, then slumped by 44.76% to -$90.9 million in 2025.
  • Its Net Income towards Common Stockholders was -$90.9 million in Q3 2025, compared to -$84.7 million in Q2 2025 and -$65.0 million in Q1 2025.